Other reviews have nicely addressed different clinical trials based on different pathways and targets affected in lung cancer, such as PI3K, mTOR, BRAF, MEK, MET, HSP90 (Heat shock protein 90) which will not be discussed here [28], in spite that some drugs described in this review could be tested in combination with K-RAS inhibitors or tested in K-RAS mutant patients as combinational therapies. The gene discussed is BRAF; the disease is lung carcinoma.